MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究

doi:10.13701/j.cnki.kqyxyj.2024.03.009

口腔医学研究 ›› 2024, Vol. 40 ›› Issue (3): 236-241.DOI: 10.13701/j.cnki.kqyxyj.2024.03.009

MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究

卢芳¹, 宁彤彤², 王婕³, 赵嘉³, 房静⁴, 宁倩倩^3*, 李家锋^1,5*

1.徐州医科大学口腔医学院江苏徐州 221004;
2.山东省第二康复医院急诊科山东泰安 271000;
3.徐州医科大学肿瘤研究所江苏徐州 221004;
4.河南科技学院河南新乡 453003;
5.徐州医科大学附属医院口腔科江苏徐州 221006

收稿日期:2023-11-08 出版日期:2024-03-28 发布日期:2024-03-25
通讯作者: * 宁倩倩,E-mail:qqning@xzhmu.edu.cn;李家锋,E-mail:jiafengli203@163.com
作者简介:卢芳(1998~ ),女,湖南益阳人,硕士在读,住院医师,研究方向:口腔颌面外科。
基金资助:
江苏省高等教育自然科学研究项目(编号:22KJB32025);徐州市科学技术局重点研发计划(社会发展)-医药卫生面上项目(编号KC22217)

Prognostic Correlation Study of MYO5A Exon 35 Skipping in Head and Neck Squamous Cell Carcinoma

LU Fang¹, NING Tongtong², WANG Jie³, ZHAO Jia³, FANG Jing⁴, NING Qianqian^3*, LI Jiafeng^1,5*

1. School of Stomatology, Xuzhou Medical University, Xuzhou 221004, China;
2. Department of Emergency, Shandong Second Rehabilitation Hospital, Taian 271000, China;
3. Cancer Institute, Xuzhou Medical University, Xuzhou 221004, China;
4. Henan Institute of Science and Technology, Xinxiang 453003, China;
5. Department of Stomatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China

Received:2023-11-08 Online:2024-03-28 Published:2024-03-25

摘要/Abstract

摘要： 目的:探讨MYO5A基因在头颈鳞状细胞癌(head and neck squamous cell carcinoma, HNSCC)中作为预后分子标志物的潜力。方法:从TCGA数据库下载HNSCC队列的RNA-Seq数据及相应的临床数据,单变量Cox回归分析MYO5A与患者预后之间的关系。从TCGA SpliceSeq数据库下载MYO5A基因的可变剪接类型,根据剪接百分比(percent spliced in,PSI)值识别差异性表达的MYO5A基因的可变剪接,并分析其与HNSCC患者预后的相关性。最后通过RT-PCR和Sanger测序在细胞系及徐州医科大学附属医院临床样本中进一步验证。结果:MYO5A基因在HNSCC队列中显著高表达,但MYO5A基因整体表达水平并不能作为独立的HNSCC预后风险指标。MYO5A 35号外显子跳跃在HNSCC中发生频率增加,且与预后密切相关。MYO5A 35号外显子跳跃在细胞系及临床样本中均得到了验证。结论:MYO5A 35号外显子跳跃而不是MYO5A基因整体表达水平可作为HNSCC预后独立的分子标志物。

关键词: MYO5A, 头颈鳞状细胞癌, 可变剪接, 预后

Abstract: Objective: To explore the potential of MYO5A gene as a prognostic molecular marker in head and neck squamous cell carcinoma (HNSCC). Methods: RNA-Seq data and corresponding clinical data were downloaded from the TCGA database for the HNSCC queue, and the relationship between MYO5A and patient prognosis was analyzed using univariate Cox regression. The variable splicing types of the MYO5A gene were downloaded from the TCGA SpliceSeq database, the variable splicing of the differentially expressed MYO5A gene was identified based on the percentage spliced in (PSI) value, and its correlation with the prognosis of HNSCC patients was analyzed. Finally, RT-PCR and Sanger sequencing were validated in clinical samples from cell lines and affiliated hospitals of Xuzhou Medical University. Results: The MYO5A gene was significantly overexpressed in the HNSCC cohort, but the overall expression level of the MYO5A gene could not be used as an independent prognostic risk indicator for HNSCC. The frequency of MYO5A exon 35 hopping was increased in HNSCC and was closely related to prognosis. The jump of MYO5A exon 35 was validated in both cell lines and clinical samples. Conclusion: The jump of MYO5A exon 35 rather than the overall expression level of MYO5A gene can serve as an independent molecular marker for the prognosis of HNSCC.

Key words: MYO5A, head and neck squamous cell carcinoma, alternative splicing, prognosis

卢芳, 宁彤彤, 王婕, 赵嘉, 房静, 宁倩倩, 李家锋. MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究[J]. 口腔医学研究, 2024, 40(3): 236-241.

LU Fang, NING Tongtong, WANG Jie, ZHAO Jia, FANG Jing, NING Qianqian, LI Jiafeng. Prognostic Correlation Study of MYO5A Exon 35 Skipping in Head and Neck Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2024, 40(3): 236-241.

参考文献

[1] Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors [J]. Br Dent J, 2022, 233(9): 780-786.
[2] Kiong KL, De Souza NN, Sultana R, et al. Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck [J]. Laryngoscope, 2018, 128(7): 1594-1601.
[3] Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [J]. Lancet Oncol, 2021, 22(4): 450-462.
[4] Sakai A, Ando M, Fukusumi T, et al. Aberrant expression of CPSF1 promotes head and neck squamous cell carcinoma via regulating alternative splicing [J]. PLoS One, 2020, 15(5): e0233380.
[5] Xing L, Zhang X, Tong D. Systematic profile analysis of prognostic alternative messenger RNA splicing signatures and splicing factors in head and neck squamous cell carcinoma [J]. DNA Cell Biol, 2019, 38(7): 627-638.
[6] Dolce LG, Silva-Junior RMP, Assis LHP, et al. Myosin Va interacts with the exosomal protein spermine synthase [J]. Biosci Rep, 2019, 39(3):BSR20182189.
[7] Huang K, Chen S, Xie R, et al. Identification of three predictors of gastric cancer progression and prognosis [J]. FEBS Open Bio, 2020, 10(9): 1891-1899.
[8] Chi H, Xie X, Yan Y, et al. Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC [J]. Front Immunol, 2022, 13: 1018685.
[9] Zhang Y, Qian J, Gu C, et al. Alternative splicing and cancer: a systematic review [J]. Signal Transduct Target Ther, 2021, 6(1): 78.
[10] Xu W, Wang X, Wu X, et al. Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis [J]. Aging (Albany NY), 2020, 12(16): 16420-16436.
[11] Cunningham F, Allen JE, Allen J, et al. Ensembl 2022 [J]. Nucleic Acids Res, 2022, 50(D1): D988-D995.
[12] Wong S, Weisman LS. Roles and regulation of myosin V interaction with cargo [J]. Adv Biol Regul, 2021, 79: 100787.
[13] Diaz-Valencia JD, Estrada-Abreo LA, Rodríguez-Cruz L, et al. Class Ⅰ Myosins, molecular motors involved in cell migration and cancer [J]. Cell Adh Migr, 2022, 16(1): 1-12.
[14] Carew JA, Cristofaro V, Dasari SP, et al. Myosin 5a in the urinary bladder: Localization, splice variant expression, and functional role in neurotransmission [J]. Front Physiol, 2022, 13: 890102.
[15] Shi DM, Dong SS, Zhou HX, et al. Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma [J]. Cell Signal, 2023, 104: 110565.
[16] Song D, Ye Z, Chen F, et al. circFNDC3B promotes esophageal squamous cell carcinoma progression by targeting MYO5A via miR-370-3p/miR-136-5p [J]. BMC Cancer, 2023, 23(1): 821.
[17] Zhu Y, Zheng S, Zhai X, et al. Comprehensive landscape of prognostic significance and immune characteristics of myosins in squamous cell carcinoma of the head and neck [J]. J Immunol Res, 2022, 2022: 5501476.
[18] Sneeggen M, Guadagno NA, Progida C. Intracellular transport in cancer metabolic reprogramming [J]. Front Cell Dev Biol, 2020, 8: 597608.
[19] Engevik KA, Engevik MA, Engevik AC. Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis [J]. PLoS One, 2023, 18(1): e0280428.
[20] Kravtsov D, Mashukova A, Forteza R, et al. Myosin 5b loss of function leads to defects in polarized signaling: implication for microvillus inclusion disease pathogenesis and treatment [J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(10): G992-G1001.

MYO5A 35号外显子跳跃对头颈鳞状细胞癌患者的预后相关研究

Prognostic Correlation Study of MYO5A Exon 35 Skipping in Head and Neck Squamous Cell Carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	房敏健, 刘亮, 邱若兰, 曹伟, 葛素云, 柴大敏. 肿瘤间质比在口腔鳞状细胞癌患者预后评估中的价值分析[J]. 口腔医学研究, 2024, 40(3): 242-247.
[2]	陈河林, 舒佳玉, 董强. CENPN对头颈鳞状细胞癌患者预后的预测价值研究[J]. 口腔医学研究, 2023, 39(8): 690-695.
[3]	杨可, 孙雅楠, 胡雅英, 吕宜楠, 郑小风, 李易玮, 张佳莉. cyclin D1表达模式深度学习识别和预测模型对HPV阴性口腔鳞状细胞癌和口咽鳞状细胞癌患者预后的预测作用[J]. 口腔医学研究, 2023, 39(4): 308-315.
[4]	李芷, 陈伟. Notch信号通路在腺样囊性癌中的研究进展[J]. 口腔医学研究, 2023, 39(12): 1042-1045.
[5]	郎雪莲, 胡涛. 恒牙活髓切断术-从基础到临床的新进展[J]. 口腔医学研究, 2023, 39(10): 866-870.
[6]	蒋志敏, 马国武, 孙波. Nomogram预测根治性切除局部晚期口腔鳞状细胞癌患者的预后[J]. 口腔医学研究, 2023, 39(1): 56-61.
[7]	张慧, 姜文敬, 王梦瑶, 李林林, 闫波, 高黎. 68例儿童恒牙外伤预后的回顾性研究[J]. 口腔医学研究, 2022, 38(7): 678-681.
[8]	吕宜楠, 胡雅英, 郑小风, 杨可, 张佳莉. IL-12A和EBI3在OSCC中的表达及其与免疫微环境的关系[J]. 口腔医学研究, 2022, 38(6): 533-539.
[9]	齐元莉, 闫红娟, 祖木热提古丽·阿不来提, 张超杰, 赵举红, 徐江. 口腔鳞状细胞癌中CASZ1的表达及临床意义[J]. 口腔医学研究, 2022, 38(1): 30-33.
[10]	周伟, 汤雅, 李厚轩, 陈斌, 闫福华. 牙周牙髓联合病变患牙预后观察的回顾性研究[J]. 口腔医学研究, 2021, 37(9): 825-829.
[11]	黄汉韬, 王晓璇, 江晨曦, 马莉, 姚斯琦, 刘欢, 曹正国. 成牙骨质细胞矿化过程中可变剪接事件分析[J]. 口腔医学研究, 2021, 37(7): 632-636.
[12]	张旭, 刘佳文. MMP-9、COX-2、NF-κB在口腔鳞状细胞癌组织中的表达及意义[J]. 口腔医学研究, 2021, 37(4): 360-365.
[13]	杨凯成, 杨蕾, 赵建广, 罗风玉, 陈彦平, 崔子峰, 陈赫, 满莎莎. 口腔鳞状细胞癌患者外周血microRNA的表达及预后意义[J]. 口腔医学研究, 2020, 36(5): 428-432.
[14]	孙振龙, 薛鹏, 遆云飞. 牙根发育完成自体牙移植远期预后及影响因素分析[J]. 口腔医学研究, 2020, 36(5): 449-453.
[15]	邹会会, 徐文光, 尹西腾, 韩伟, 江琳琳. 基于SEER数据库分析影响大唾液腺腺样囊性癌患者预后的临床病理因素[J]. 口腔医学研究, 2020, 36(2): 167-171.